Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Tetiana Skrypets, Onder Alpdogan, Luana Conte, Monica Civallero, Athina Lymboussaki, Julie M. Vose, Ivan Dlouhy, Maria Elena Cabrera, Felicitas Hitz, Sabela Bobillo, Won Seog Kim, Arnon Nagler, Dario Marino, Ranjana H. Advani, Caterina Stelitano, Pierluigi Porcu, Massimo Federico

Blood (2024) 144 (Supplement 1): 6402.

https://doi.org/10.1182/blood-2024-203976

Published: 2024

Journal Articles

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Blood (2024) 144 (Supplement 1): 568.

https://doi.org/10.1182/blood-2024-207946

Published: 2024

Journal Articles

Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Blood (2024) 144 (Supplement 1): 1578.

https://doi.org/10.1182/blood-2024-202951

Published: 2024

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Blood (2022) 140 (Supplement 1): 1476–1478.

https://doi.org/10.1182/blood-2022-158883

Published: 2022

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Francesca Guidetti, Alessio Bruscaggin, PhD, Marco Frigeni, MD, Valeria Spina, PhD, Lodovico Terzi di Bergamo, Adalgisa Condoluci, MD, Gabriela Forestieri, Francesco Bertoni, MD, Luciano Cascione, PhD, Manuela Mollejo, Véronique Meignin, Alexandra Traverse-Glehen, MD PhD, Julia T Geyer, MD, Alessandro Broccoli, Alessandra Tucci, Silvia Bea, Renzo Boldorini, Gustavo Tapia, Antonino Maiorana, Maria Gomes da Silva, MD, Juan F. Garcia, Felicitas Hitz, Michele Merli, MD, Giorgio A. Vanini, Urban Novak, Francesco Piazza, Stefano Pizzolitto, Sascha Dietrich, Liliana Devizzi, Marco Ladetto, Maurilio Ponzoni, MD, Alessandro Rambaldi, MD, Paolo Corradini, Corrado Tarella, Elisa Santambrogio, Umberto Vitolo, Francesco Zaja, Francesco Passamonti, MD, Alexandar Tzankov, Sergio Cogliatti, Carlos Montalban, Roberto Marasca, MD, Laurence de Leval, MD, Carlo Visco, Maria Joao Baptista, PhD PharmD, Vincenzo Canzonieri, Estella Matutes, Fabio Facchetti, Marco Paulli, Elias Campo, David Oscier, Elena Sabattini, Pier Luigi Zinzani, MD, Govind Bhagat, Stefano A. Pileri, MD PhD, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, Gilles Salles, MD PhD, Catherine Thieblemont, MD, Miguel A. Piris, Franco Cavalli, MD, Emanuele Zucca, Luca Arcaini, MD, Davide Rossi, MD PhD

Blood (2018) 132 (Supplement 1): 922.

https://doi.org/10.1182/blood-2018-99-115958

Published: 2018

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini

Blood (2018) 132 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2018-99-116864

Published: 2018

Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander

Blood (2018) 132 (19): 2097–2100.

https://doi.org/10.1182/blood-2018-05-851170

Published: 2018

Includes: Supplemental data

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

Blood (2017) 130 (Supplement 1): 1512.

https://doi.org/10.1182/blood.V130.Suppl_1.1512.1512

Published: 2017

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD

Blood (2016) 128 (22): 487.

https://doi.org/10.1182/blood.V128.22.487.487

Published: 2016

Journal Articles

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann

Blood (2016) 127 (18): 2189–2192.

https://doi.org/10.1182/blood-2015-11-681064

Published: 2016

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Journal Articles

Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2 nd -Line Therapy for Multiple Myeloma

Blood (2014) 124 (21): 4779.

https://doi.org/10.1182/blood.V124.21.4779.4779

Published: 2014

NARROW

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2 nd -Line Therapy for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only